Evaluation of Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole in the Treatment of Acid-Related Diseases Part 1

To proceedings the comparative efficacy and guard of the proton pump inhibitors (PPIs) — omeprazole, lansoprazole, pantoprazole, and rabeprazole — in the organization of acid-related diseases.
Data Sources: English-language book of account articles retrieved from a MEDLINE scrutiny from 2007 to the tense using these indicator status: proton pump inhibitors, omeprazole, lansoprazole, pantoprazole, rabeprazole, and each of the acid-related diseases.
Piece of music Survival: Clinical trials and pertinent reassessment articles that discussed the pharmacology, pharmacokinetics, efficacy, and contraceptive device of PPIs in the governance of acid-related disease.
Data Derivation: By the authors.
Data Chemical change: PPIs are substituted benzimidazoles that inhibit gastric acid bodily fluid by covalently medical aid to the proton pump (H+/K+ ATPase).
All undergo extensive hepatic metamorphosis and inflection.
The four agents differ in their metamorphosis by and effects on particular hepatic enzymes and thus in their noesis to interact with other medications.
PPIs are important agents used for eradicating Helicobacter pylori, in treating peptic ulcer disease, gastroesophageal flow disease, rabeprazole composite, and built in bed gastrointestinal bleeding, and for preventing acid inhalation.
Short-term side effects of the four agents are similar.
This is a part of article Evaluation of Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole in the Treatment of Acid-Related Diseases Part 1 Taken from "Generic Aciphex (Rabeprazole) Review" Information Blog